Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma’s strategy to diversify its business and invest in renewable energy.<\/p>\n
The company had initially planned to complete the acquisition by a certain deadline, but it has now been extended due to various reasons. The extension of the timeline is expected to give Aurobindo Pharma more time to complete the necessary formalities and regulatory approvals.<\/p>\n
Aurobindo Pharma is one of the leading pharmaceutical companies in India, and its decision to invest in Swarnaakshu Solar marks a significant departure from its core business. The company has been looking to diversify its portfolio and reduce its dependence on the pharmaceutical sector.<\/p>\n
Swarnaakshu Solar is a solar power company that specializes in the development and operation of solar power plants. The company has a strong presence in the Indian renewable energy market and has developed several solar power projects across the country.<\/p>\n
The acquisition of a 26% stake in Swarnaakshu Solar is expected to give Aurobindo Pharma a significant foothold in the renewable energy sector. The company plans to use the investment to expand its presence in the solar power market and to reduce its carbon footprint.<\/p>\n
The extension of the timeline to acquire a stake in Swarnaakshu Solar is not expected to have a significant impact on Aurobindo Pharma’s financial performance in the short term. However, the investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.<\/p>\n
Aurobindo Pharma’s decision to invest in Swarnaakshu Solar is part of a larger trend of pharmaceutical companies diversifying their business and investing in renewable energy. The investment is expected to help the company to reduce its dependence on fossil fuels and to achieve its sustainability goals.<\/p>\n
Overall, the extension of the timeline to acquire a stake in Swarnaakshu Solar is a positive development for Aurobindo Pharma and marks a significant step forward in the company’s strategy to diversify its business and invest in renewable energy. The investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.<\/p>\n","protected":false},"excerpt":{"rendered":"
Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma’s strategy to diversify its business and invest in renewable energy. The company had initially planned to complete the acquisition by a certain deadline, but it has now been extended due […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21,2],"tags":[],"class_list":["post-89749","post","type-post","status-publish","format-standard","hentry","category-aurobindo-pharma","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89749,"position":0},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89658,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/13\/will-aurobindo-pharma-limiteds-new-product-launches-drive-revenue-growth-in-year-quarterly-earnings-analysis-profit-outlook-on-earlytimes-in\/","url_meta":{"origin":89749,"position":1},"title":"Will Aurobindo Pharma Limited’s New Product Launches Drive Revenue Growth in YEAR – Quarterly Earnings Analysis & Profit Outlook on earlytimes.in","author":"Team Small News","date":"December 13, 2025","format":false,"excerpt":"Aurobindo Pharma Limited, a leading pharmaceutical company, is expected to witness a significant boost in revenue due to the launch of new products. The company has been consistently expanding its product portfolio, and the latest launches are anticipated to contribute substantially to its top-line growth. In this article, we will\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89778,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/10\/mylan-and-aurobindo-pharma-must-defend-against-allegations-of-colluding-to-fix-prices-for-generic-drugs\/","url_meta":{"origin":89749,"position":2},"title":"Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.","author":"Team Small News","date":"January 10, 2026","format":false,"excerpt":"A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89749,"position":3},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89660,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/13\/does-piramal-pharma-limited-possess-sustainable-competitive-advantages-for-sustained-long-term-expansion-analyzing-earnings-trends-capitalizing-on-exceptional-growth-opportunities\/","url_meta":{"origin":89749,"position":4},"title":"Does Piramal Pharma Limited Possess Sustainable Competitive Advantages for Sustained Long-Term Expansion – Analyzing Earnings Trends & Capitalizing on Exceptional Growth Opportunities","author":"Team Small News","date":"December 13, 2025","format":false,"excerpt":"Piramal Pharma Limited, a leading pharmaceutical company, has been exhibiting remarkable growth patterns, making it an attractive investment opportunity. To determine if the company has competitive moats for long-term growth, it's essential to analyze its earnings growth patterns and market trends. Piramal Pharma has demonstrated a strong track record of\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Piramal-Healthcare.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":89792,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/piramal-pharma-enhances-its-global-sustainability-rating-in-recent-corporate-assessment\/","url_meta":{"origin":89749,"position":5},"title":"Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company's sustainability performance, evaluating factors such as environmental, social, and governance (ESG) practices. In\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Piramal-Healthcare.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89749"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89749\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}